GH Research PLC (NASDAQ:GHRS – Get Free Report) shares traded down 6.9% during mid-day trading on Tuesday after HC Wainwright lowered their price target on the stock from $65.00 to $55.00. HC Wainwright currently has a buy rating on the stock. GH Research traded as low as $17.97 and last traded at $17.7870. Approximately 15,632 shares traded hands during trading, a decline of 95% from the average session volume of 305,740 shares. The stock had previously closed at $19.10.
Several other brokerages also recently commented on GHRS. Needham & Company LLC increased their target price on shares of GH Research from $32.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Zacks Research raised shares of GH Research from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Wall Street Zen upgraded shares of GH Research from a “sell” rating to a “hold” rating in a report on Saturday, November 14th. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a report on Thursday, October 15th. Finally, Wells Fargo & Company started coverage on shares of GH Research in a research report on Monday, July 27th. They issued an “overweight” rating and a $44.00 price objective for the company. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, GH Research presently has an average rating of “Moderate Buy” and a consensus price target of $44.00.
Read Our Latest Stock Analysis on GH Research
Institutional Inflows and Outflows
GH Research Trading Down 0.1%
The stock’s fifty day moving average is $21.73 and its two-hundred day moving average is $21.68. The company has a market capitalization of $1.25 billion, a PE ratio of -19.21 and a beta of 1.31.
GH Research (NASDAQ:GHRS – Get Free Report) last posted its quarterly earnings results on Friday, November 13th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.13. As a group, analysts anticipate that GH Research PLC will post -1.20 EPS for the current fiscal year.
About GH Research
GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.
Further Reading
- Five stocks we like better than GH Research
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.
